Limas C J, Goldenberg I F, Limas C
Department of Medicine (Cardiovascular Division), University of Minnesota, School of Medicine, Minneapolis 55455.
Circ Res. 1989 Jan;64(1):97-103. doi: 10.1161/01.res.64.1.97.
Although it is recognized that the number of cardiac beta-adrenoceptors is reduced in human dilated cardiomyopathy, the mechanisms involved have not been defined. We examined the possible role of altered humoral immunity by comparing the effect of sera from patients with idiopathic dilated cardiomyopathy (n = 20), ischemic or valvular heart disease (n = 28), or controls with no known cardiac disease (n = 18) on the binding of radioligands to cardiac beta-receptors. The ability of sera from cardiomyopathic patients to inhibit the binding of [3H]dihydroalprenolol to rat cardiac membranes was significantly higher than that of the other two patient groups (40 +/- 5% at 50-fold serum dilution compared to 14 +/- 3% for the ischemic/valvular heart disease group, and 14 +/- 4% for the normal control group, p less than 0.001). A similar inhibition was exerted by IgG from cardiomyopathic patients. Only the number, not the affinity, of the beta-receptors was decreased by cardiomyopathic sera. This decrease could be prevented by preincubating the sera with anti-human IgG, indicating the presence of autoantibodies. Furthermore, the sera were ineffective against cardiac alpha 1-adrenoceptors and considerably less effective against lung beta 2-receptors. In addition to ligand binding inhibition, sera from cardiomyopathic patients could immunoprecipitate beta-adrenoceptors quantitatively from solubilized cardiac membranes. Positive sera inhibited significantly isoproterenol-stimulated adenylate cyclase with no effect on basal or NaF-stimulated activities. These results document the presence in sera from patients with idiopathic dilated cardiomyopathy of autoantibodies directed against the cardiac beta 1-adrenoceptor which may play an important role in the regulation of inotropic responsiveness to beta-agonists.
尽管人们认识到在人类扩张型心肌病中心脏β - 肾上腺素能受体数量减少,但其涉及的机制尚未明确。我们通过比较特发性扩张型心肌病患者(n = 20)、缺血性或瓣膜性心脏病患者(n = 28)或无已知心脏病的对照组(n = 18)的血清对放射性配体与心脏β受体结合的影响,研究了体液免疫改变可能发挥的作用。扩张型心肌病患者血清抑制[³H]二氢阿普洛尔与大鼠心脏膜结合的能力显著高于其他两组患者(血清稀释50倍时为40±5%,而缺血/瓣膜性心脏病组为14±3%,正常对照组为14±4%,p<0.001)。扩张型心肌病患者的IgG也有类似的抑制作用。扩张型心肌病血清仅使β受体的数量减少,而不影响其亲和力。通过将血清与抗人IgG预孵育可防止这种减少,表明存在自身抗体。此外,这些血清对心脏α₁ - 肾上腺素能受体无效,对肺β₂ - 受体的作用也明显较弱。除了配体结合抑制外,扩张型心肌病患者的血清还能从溶解的心脏膜中定量免疫沉淀β - 肾上腺素能受体。阳性血清显著抑制异丙肾上腺素刺激的腺苷酸环化酶,而对基础或NaF刺激的活性无影响。这些结果证明特发性扩张型心肌病患者血清中存在针对心脏β₁ - 肾上腺素能受体的自身抗体,其可能在β - 激动剂的变力反应调节中起重要作用。